Inventiva Sa - Adr (IVA)

$3.1001

-0.14

(-4.32%)▲

Live

Insights on Inventiva Sa - Adr

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 49.7% return, outperforming this stock by 20.1%

Performance

  • $3.10
    $3.15
    $3.10
    downward going graph

    0.0%

    Downside

    Day's Volatility :1.59%

    Upside

    1.59%

    downward going graph
  • $2.22
    $5.05
    $3.10
    downward going graph

    28.39%

    Downside

    52 Weeks Volatility :56.04%

    Upside

    38.61%

    downward going graph

Returns

PeriodInventiva Sa - AdrSector (Health Care)Index (Russel 2000)
3 Months
-17.34%
1.7%
0.0%
6 Months
-15.84%
11.3%
0.0%
1 Year
29.6%
5.4%
1.3%
3 Years
-76.86%
13.9%
-22.1%

Highlights

Market Capitalization
175.2M
Book Value
- $0.62
Earnings Per Share (EPS)
-2.59
Profit Margin
0.0%
Operating Margin TTM
-288.43%
Return On Assets TTM
-69.19%
Return On Equity TTM
-1642.76%
Revenue TTM
23.2M
Revenue Per Share TTM
0.51
Quarterly Revenue Growth YOY
7.3%
Gross Profit TTM
18.8M
EBITDA
-101.8M
Diluted Eps TTM
-2.59
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    91%Buy
    8%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for Inventiva Sa - Adr(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
11
11
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 942.98%

Current $3.10
Target $32.33

Company Financials

FY18Y/Y Change
Revenue
3.7M
↓ 50.97%
Net Income
-38.5M
↑ 95.12%
Net Profit Margin
-1.1K%
↓ 787.3%
FY19Y/Y Change
Revenue
7.8M
↑ 118.89%
Net Income
-33.9M
↓ 10.1%
Net Profit Margin
-431.85%
↑ 619.67%
FY20Y/Y Change
Revenue
457.6K
↓ 94.68%
Net Income
-38.9M
↑ 4.64%
Net Profit Margin
-8.5K%
↓ 8068.96%
FY21Y/Y Change
Revenue
4.7M
↑ 1027.42%
Net Income
-56.2M
↑ 56.96%
Net Profit Margin
-1.2K%
↑ 7317.31%
FY22Y/Y Change
Revenue
13.0M
↑ 190.39%
Net Income
-58.1M
↑ 9.34%
Net Profit Margin
-445.64%
↑ 737.86%
FY23Y/Y Change
Revenue
17.5M
↑ 43.5%
Net Income
-110.4M
↑ 103.46%
Net Profit Margin
-631.84%
↓ 186.2%
Q4 FY22Q/Q Change
Revenue
13.0M
-
Net Income
-26.6M
-
Net Profit Margin
-204.82%
-
Q2 FY23Q/Q Change
Revenue
1.9M
-
Net Income
-55.3M
-
Net Profit Margin
-2.9K%
-
Q4 FY23Q/Q Change
Revenue
15.6M
↑ 719.36%
Net Income
-55.2M
↓ 0.2%
Net Profit Margin
-354.12%
↑ 2553.24%
Q1 FY24Q/Q Change
Revenue
15.6M
↑ 0.0%
Net Income
-55.2M
↑ 0.0%
Net Profit Margin
-354.12%
↑ 0.0%
FY18Y/Y Change
Total Assets
91.3M
↑ 7.32%
Total Liabilities
20.8M
↑ 75.86%
FY19Y/Y Change
Total Assets
63.8M
↓ 28.63%
Total Liabilities
17.4M
↓ 14.54%
FY20Y/Y Change
Total Assets
170.9M
↑ 143.89%
Total Liabilities
34.1M
↑ 77.98%
FY21Y/Y Change
Total Assets
138.1M
↓ 12.19%
Total Liabilities
37.5M
↑ 19.53%
FY22Y/Y Change
Total Assets
124.3M
↓ 4.9%
Total Liabilities
75.6M
↑ 112.96%
FY23Y/Y Change
Total Assets
69.1M
↓ 40.4%
Total Liabilities
101.6M
↑ 44.05%
Q2 FY22Q/Q Change
Total Assets
113.2M
↓ 10.58%
Total Liabilities
40.4M
-
Q4 FY22Q/Q Change
Total Assets
124.3M
↑ 7.02%
Total Liabilities
75.6M
↑ 82.4%
Q2 FY23Q/Q Change
Total Assets
77.3M
↓ 38.95%
Total Liabilities
85.6M
-
Q4 FY23Q/Q Change
Total Assets
70.8M
↑ 0.0%
Total Liabilities
101.6M
↑ 29.44%
Q1 FY24Q/Q Change
Total Assets
69.1M
↓ 2.37%
Total Liabilities
101.6M
↑ 0.0%
FY18Y/Y Change
Operating Cash Flow
-39.1M
↑ 101.19%
Investing Cash Flow
-480.5K
↓ 106.81%
Financing Cash Flow
36.9M
↓ 28.32%
FY19Y/Y Change
Operating Cash Flow
-31.8M
↓ 16.96%
Investing Cash Flow
-925.3K
↑ 96.67%
Financing Cash Flow
9.4M
↓ 74.04%
FY20Y/Y Change
Operating Cash Flow
-37.6M
↑ 7.7%
Investing Cash Flow
-10.5M
↑ 935.96%
Financing Cash Flow
137.4M
↑ 1232.94%
FY21Y/Y Change
Operating Cash Flow
-53.9M
↑ 55.7%
Investing Cash Flow
-2.0M
↓ 79.05%
Financing Cash Flow
28.8M
↓ 77.21%
Q2 FY22Q/Q Change
Operating Cash Flow
-27.4M
↑ 100.0%
Investing Cash Flow
-140.0K
↑ 0.0%
Financing Cash Flow
14.6M
↑ 100.0%
Q3 FY22Q/Q Change
Operating Cash Flow
-22.6M
↓ 13.75%
Investing Cash Flow
-3.9M
↑ 2773.88%
Financing Cash Flow
-1.1M
↓ 107.72%
Q4 FY22Q/Q Change
Operating Cash Flow
-20.0M
↓ 17.29%
Investing Cash Flow
-4.1M
↑ 0.0%
Financing Cash Flow
25.0M
↓ 2265.91%
Q1 FY23Q/Q Change
Operating Cash Flow
-22.6M
↑ 20.9%
Investing Cash Flow
-3.9M
↑ 0.0%
Financing Cash Flow
-1.1M
↓ 104.62%
Q2 FY23Q/Q Change
Operating Cash Flow
-45.2M
↑ 100.0%
Investing Cash Flow
-3.9M
↑ 0.0%
Financing Cash Flow
-2.2M
↑ 100.0%

Technicals Summary

Sell

Neutral

Buy

Inventiva Sa - Adr is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Inventiva Sa - Adr
Inventiva Sa - Adr
-14.74%
-15.84%
29.6%
-76.86%
-76.86%
Moderna, Inc.
Moderna, Inc.
-1.39%
41.81%
-19.31%
-38.71%
322.88%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-5.68%
13.74%
14.81%
80.88%
159.02%
Novo Nordisk A/s
Novo Nordisk A/s
-2.24%
29.49%
49.67%
240.51%
421.0%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-3.67%
10.39%
20.74%
84.71%
129.52%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Inventiva Sa - Adr
Inventiva Sa - Adr
NA
NA
NA
0.0
-16.43
-0.69
NA
-0.62
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.77
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.13
26.13
1.46
45.02
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
48.36
48.36
2.4
3.34
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
29.17
29.17
0.53
16.75
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Inventiva Sa - Adr
Inventiva Sa - Adr
Buy
$175.2M
-76.86%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$41.3B
322.88%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$99.6B
159.02%
26.13
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$573.9B
421.0%
48.36
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$104.7B
129.52%
29.17
36.68%

Institutional Holdings

  • Yiheng Capital LLC

    5.12%

  • NEA Management Company, LLC

    2.83%

  • Bvf Inc

    1.33%

  • Commonwealth Equity Services Inc

    0.07%

  • TWO SIGMA SECURITIES, LLC

    0.03%

  • EWA, LLC

    0.02%

Corporate Announcements

  • Inventiva Sa - Adr Earnings

    Inventiva Sa - Adr’s price-to-earnings ratio stands at None

    Read More

Company Information

Organization
Inventiva Sa - Adr
Employees
120
CEO
Dr. Pierre Broqua Ph.D.
Industry
Health Technology

Discover More

FAQs